Brief: Brainsway Says Study Shows Advantages Of Co's Deep TMS In Treating Major Depressive Disorder
18/07/2019 15:01
July 18 (Reuters) - Brainsway Ltd BWAY.TA :
* GROUNDBREAKING STUDY DEMONSTRATES ADVANTAGES OF BRAINSWAY
DEEP
TMS IN TREATING MAJOR DEPRESSIVE DISORDER
* BRAINSWAY LTD - RESPONSE RATE WAS SIGNIFICANTLY GREATER
WITH
DTMS PLUS PHARMACOTHERAPY (66.7%) THAN WITH STANDARD RTMS PLUS
PHARMACOTHERAPY (44.0%)
* BRAINSWAY LTD - THERE WAS A TREND TOWARD IMPROVED
REMISSION RATE
WITH DTMS (59.7%) COMPARED WITH STANDARD RTMS
* BRAINSWAY LTD - NO DIFFERENCE WAS SEEN IN SAFETY OR
TOLERABILITY
BETWEEN DTMS AND STANDARD RTMS
Source text for Eikon: ID:nGNXjjg1r
Further company coverage: BWAY.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brainsway
See all newsBrief: Brainsway Presents Positive Data From Largest Real-World Study Of Deep Tms™ In Patients With Comorbid Ptsd And Major Depressive Disorder
Brief: Brainsway Announces Minority-Stake Investment In Hopemark Health
Brief: Brainsway Announces New Minority-Stake Investment In Canadian Provider, Brainstim Health Inc.
Brief: Brainsway Announces Change In ADS-To-Ordinary Share Ratio
Brief: BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)